

Biographical Sketch

David E. Moller, M.D.

David Moller is Vice President of Endocrine and Cardiovascular Research and Clinical Investigation at Eli Lilly. In his current position, he oversees discovery and early clinical (Phase I-II) development efforts in Diabetes, Obesity, Cardiovascular, and Musculoskeletal research. He has participated in industry-academic partnerships as well in executing-overseeing several corporate partnerships (e.g. Transition Therapeutics, Prosidion-OSI, ShangPharma, Biodura, Jubilant-Biosys, Piramal Lifesciences). Currently, Dr. Moller is also overseeing a new research center being established by Lilly in Shanghai.

Prior to joining Lilly in 2005, Dr. Moller worked at Merck Research Laboratories as Vice President, Metabolic Disorders and was responsible for oversight and coordination of global diabetes and obesity research efforts. Dr. Moller's team delivered several additions to the pipeline including Sitagliptin (Januvia™) and additional diabetes and obesity mechanisms which progressed into clinical development.

David Moller, graduated from Brown University and received his medical degree from the University of Cincinnati. He completed a residency in Internal Medicine at George Washington University. Following his fellowship in Endocrinology at Harvard Medical School, Dr. Moller joined the Harvard faculty. From 1989-1995, his laboratory research yielded several important clues to the molecular pathogenesis of obesity and diabetes, including the discovery of novel mutations in the insulin receptor gene which were causative for inherited insulin resistance.

Dr. Moller has published more than one hundred peer-reviewed papers. He is a member of various professional societies and was elected as a member of the American Society of Clinical Investigation; he is also an adjunct (honorary) professor at the Karolinska Institute in Stockholm.